Mark Gotfried
Pulmonary Disease · Phoenix, AZNPI 1952353658
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,448 of the $196,320 with a category attached, or 92.9%. GSK accounts for 74.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $74,710 and has fallen 99.9% since, to $43 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $853.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$147K
- Idorsia Pharmaceuticals US Inc$46K
- Mylan Specialty L.p.$2K
- Insmed, Inc.$1K
- Sunovion Pharmaceuticals Inc.$133
- ZOLL Respicardia, Inc.$124
- plus $148 from 4 others
Across 207 payments — averaging $4273.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$245K
- Takeda Pharmaceuticals U.S.A., Inc.$221K
- Eisai Inc.$196K
- Melinta Therapeutics, LLC$71K
- CSL Behring$70K
- AstraZeneca$66K
- plus $16K from 2 others
What the payments were for
- Consulting fees$4500%
- Speaking & faculty fees$182,44893%
- Travel & lodging$11,2096%
- Food & beverage$2,1491%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 126 | $147,018 |
| Idorsia Pharmaceuticals US Inc | 79 | $45,872 |
| Mylan Specialty L.p. | 1 | $1,800 |
| Insmed, Inc. | 3 | $1,224 |
| Sunovion Pharmaceuticals Inc. | 6 | $133 |
| ZOLL Respicardia, Inc. | 6 | $124 |
| Gilead | 4 | $53 |
| Genentech USA, Inc. | 2 | $43 |
| Bayer | 2 | $38 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$84,064
- QUVIVIQ$44,092
- NUCALA$23,656
- ANORO ELLIPTA$18,000
- ANORO$11,354
- Yupelri$1,800
- Arikayce$1,125
How this compares
$196,320 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.